Uttar Pradesh-based veterinary pharmaceutical company Rodec Pharma has filed draft document with capital markets regulator SEBI to raise funds via Initial Public Offering (IPO) with no fresh issue component.
The IPO will be entirely an offer-for-sale of 56.5 lakh shares by promoter Mukesh Kumar Gupta. Hence, the company will not receive any funds from the offer.
The main objects of the public issue are to carry out the offer-for-sale, and achieve the benefits of listing equity shares on stock exchange.
Incorporated in 1997, Rodec Pharma that manufactures animal feed supplements and markets veterinary pharmaceutical drugs and animal feed supplements to veterinarians, animal healthcare providers, and livestock farmers has manufacturing facility in Ghaziabad, Uttar Pradesh.
The animal feed supplements business contributed around 40 percent of the company’s revenue, while pharmaceutical drugs—such as analgesics and antipyretics, anthelmintics, and antibiotics—accounted for about 55 percent of the topline.
Click Here To Read All IPO News
The company recorded profit of Rs 9.7 crore on revenue of Rs 62.7 crore for six months period ended September 2025. Further, profit in fiscal 2025 grew by 65.4 percent to Rs 18.3 crore, up from Rs 11 crore in previous year, while revenue during the same period increased 20.3 percent to Rs 106.4 crore, up from Rs 88.4 crore.
Khambatta Securities is appointed as the merchant banker for the Rodec Pharma IPO.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
